Alzheimer's Disease and Dementia
Our work in Alzheimer's Disease and Dementia
Interdisciplinary Panel Offers Solutions to Improve Recruitment for Alzheimer’s Clinical Trials
Experts from the private and public sectors convened a panel to improve recruitment for Alzheimer’s clinical trials.Categorized in
Recommendations To Address Key Recruitment Challenges of Alzheimer’s Disease Clinical Trials
An advisory panel of experts convened in 2020 to assess the critical challenges facing recruitment in Alzheimer’s clinical trials and develop a set of recommendations to overcome them.
Benzodiazepine Use and the Risk of Dementia
There is little evidence that older adults prescribed benzodiazepines—drugs commonly used to treat anxiety, insomnia and seizures—are at increased risk of developing dementia.
Benzodiazepines Don’t Increase Dementia Risks in Older Adults, USC Study Finds
There is little evidence that older adults prescribed benzodiazepines are at increased risk of developing dementia.
Access to Disease-Modifying Alzheimer’s Therapies: Addressing Possible Challenges Using Innovative Payment Models
Researchers use the Future Elderly Model to estimate potential benefits of disease-modifying therapies for Alzheimer disease.Categorized in
Race and Ethnic Differences in the Association Between Alzheimer’s Disease Risk and Use of Prescription Medications for Chronic Conditions
Schaeffer Center experts analyze the connection between medications for chronic diseases and their impact on Alzheimer’s as well as a lack of representation among racial and ethnic minorities in clinical trials.Categorized in
The Unequal Causes and Costs of Dementia
Dementia and its costs aren’t equally borne by all populations. Studies indicate that, compared to older non-Hispanic white adults, older Black adults are about twice as likely to have dementia, and older Hispanic adults about one and one-half times as likely.Categorized in
The Science of Alzheimer’s Disease and Related Dementias (ADRD) for Social Scientists Program
This two-day program aims to provide social science researchers with biomedical and clinical foundations of ADRD.Categorized in
Interdisciplinary Hub Fosters Innovative Solutions for Improving Diversity in Clinical Trials
USC has received $5.8 million from Gates Ventures and the American Heart Association to launch a lab aimed at diversifying clinical trials.Categorized in
Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers
Developing a blueprint to overcome challenges in implementing new payment models will ensure better access.Categorized in